ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Jan 18th, 2022 - To analyse the cytopathological features of fine-needle aspiration (FNA) in angioimmunoblastic T-cell lymphoma (AITL) diagnostics. FNA lymph node biopsy samples from 12 patients with AITL were collected at a single centre between January 2014 and ...

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

Jan 3rd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Dec 31st, 2021 - A 59-year-old woman presented with a persistent eruption manifested as multiple agminated miliary facial papules. Histopathological examination showed prominent nodular dermal lymphoid infiltrates with hyperplastic follicles that were initially in...

Dec 22nd, 2021 - It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining f...

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

Jan 3rd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Dec 7th, 2021 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

Jul 8th, 2021 - This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two...

Jun 18th, 2021 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...

Dec 13th, 2021 - The combination of duvelisib (Copiktra) plus romidepsin (Istodax; DR) was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma (PTCL), according to final results from the dose expansion stage of a phase 1 trial (NCT027836...

Feb 17th, 2021 - Questions from the phase 3 ECHELON-2 trial (NCT01777152), which led to the 2018 FDA approval of brentuximab vedotin (Adcetris) plus chemotherapy for patients with CD30-expressing peripheral T-cell lymphoma (PTCL), have given way to additional rese...

Dec 20th, 2020 - The anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AIT...

Dec 6th, 2020 - In patients with T-cell lymphoma, allogeneic transplant can lead to durable remissions among patients who might otherwise have poor outcomes, results of a large retrospective observational study suggest. Five-year progression-free survival (PFS) a.

Nov 16th, 2020 - The emergence of brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (CHP) in the treatment armamentarium for advanced peripheral T-cell lymphoma (PTCL) led to a shift in the paradigm for patients with CD30 positivity...